Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis.

Objective: The aim of this study was to investigate the effect of dapagliflozin (DAPA) on the rate of heart failure rehospitalization in patients with acute myocardial infarction (AMI) and type 2 diabetes mellitus (T2DM). Methods: AMI patients with T2DM from CZ-AMI registry between January 2017 and...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Pharmacology Vol. 79; no. 7; pp. 915 - 927
Autores principales: Mao, Lipeng, Cai, Dabei, Chi, Boyu, Xiao, Tingting, Zou, Ailin, Wang, Yu, Chen, Qianwen, Gu, Qingqing, Wang, Qingjie, Ji, Yuan, Sun, Ling
Formato: research tables/charts Journal Article
Publicado: Springer Nature Jul2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=164373294&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 164373294
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Jul2023
      vid: 79
      iid: 7
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        164373294
        163333034
        164373294
        164373294
        10.1007/s00228-023-03495-3
        164373294
      ppf: 915
      ppct: 12
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis.
      aug:
        au:
          Mao, Lipeng
          Cai, Dabei
          Chi, Boyu
          Xiao, Tingting
          Zou, Ailin
          Wang, Yu
          Chen, Qianwen
          Gu, Qingqing
          Wang, Qingjie
          Ji, Yuan
          Sun, Ling
        affil: Department of Cardiology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, 29 Xinglong Alley, 213000, Changzhou, Jiangsu, China
      sug:
        subj:
          Myocardial Infarction Drug Therapy
          Diabetes Mellitus, Type 2 Drug Therapy
          Dapagliflozin Therapeutic Use
          Heart Failure Epidemiology
          Heart Failure Risk Factors
          Readmission Evaluation
          Drug Efficacy Evaluation
          Risk Assessment
          Human
          China
          Comparative Studies
          Kaplan-Meier Estimator
          Cox Proportional Hazards Model
          Descriptive Statistics
          Multivariate Analysis
          Confidence Intervals
          Survival Analysis
          Funding Source
      ab: Objective: The aim of this study was to investigate the effect of dapagliflozin (DAPA) on the rate of heart failure rehospitalization in patients with acute myocardial infarction (AMI) and type 2 diabetes mellitus (T2DM). Methods: AMI patients with T2DM from CZ-AMI registry between January 2017 and January 2021 were enrolled in this study. Patients were stratified into DAPA users and non-DAPA users. The primary outcome was the incidence of heart failure rehospitalization. Kaplan–Meier analysis and Cox regressions were performed to evaluate the prognostic significance of DAPA. Propensity score matching (PSM) was performed to minimize the bias of confounding factors and facilitate the comparability between groups. The enrolled patients were matched with a propensity score of 1:1. Results: A total of 961 patients were included, and 132 (13.74%) heart failure rehospitalizations occurred during a median follow-up of 540 days. In the Kaplan–Meier analysis, DAPA users had a statistically significantly lower rate of heart failure rehospitalization than non-DAPA users (p < 0.0001). Multivariate Cox analysis showed that DAPA was an independent protective factor for heart failure rehospitalization risk after discharge (HR = 0.498, 95% CI = 0.296 ~ 0.831, p = 0.001). After 1:1 propensity score matching, survival analysis showed a lower cumulative risk of heart failure rehospitalization in DAPA users than in non-DAPA users (p = 0.0007). In-hospital and continued use of DAPA remained significantly associated with a reduced risk of heart failure rehospitalization (HR = 0.417, 95% CI = 0.417 ~ 0.838, p = 0.001). Results were consistent across sensitivity and subgroup analyses. Conclusion: In patients with diabetic AMI, in-hospital and continued use of DAPA after discharge were associated with a significant lower risk of heart failure rehospitalization.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N